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ABSTRACT
Objectives: The present study evaluates the prognostic value of metabolic parameters related to the primary tumor identi-
fied in preoperative fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) scans in 
patients with endometrial cancer (EC). 
Material and methods: This study included 120 patients with EC who underwent PET/CT in the preoperative period. The 
patients’ age, maximum standardized uptake value (SUVmax), SUVmean, metabolic tumor volume (MTV) and the total 
lesion glycolysis (TLG) value of the primary tumor on PET/CT; as well as the stage, histological subtype, grade and size of 
the primary EC; the degree of myometrial invasion (MI) cervical invasion (CI), lymphovascular invasion (LVI), lymph node 
metastasis (LNM) and distant metastasis (DM) were all recorded. The relationship of these factors with progression-free 
survival (PFS) and overall survival (OS) was evaluated.
Results: The study included 120 patients with EC with a mean age of 62.3 ± 0.02 years. Of the total, 32 patients died 
around the time of the analysis and 38 patients showed disease progression. The mean OS was 32.7 ± 1.6 months and the 
mean PFS was 30.5 ± 2.8 months. No significant relationship was identified between the SUVmax, SUVmean, MTV, TLG 
values, patient age, tumor size, histology, grade and MI degree, and OS or PFS. Disease stage, LVI, CI, LNM and DM were 
identified as prognostic factors for OS and PFS.
Conclusions: The present study found no significant relationship between preoperative PET parameters in EC and OS and 
PFS, although prospective studies involving a larger number of patients are required.
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INTRODUCTION
Endometrial cancer (EC) is the most common gynecologi-
cal malignancy in developed countries [1]. The majority of pa-
tients are diagnosed in the early stage [2], and early-stage EC 
has a good prognosis with 5-year survival reaching 90% [3, 4]. 
That said, the rate of recurrence and the risk of death are 
high in advanced-stage EC [5] with the 5-year survival in the 
range of 20–26% in stage 4 EC [6]. Aside from disease stage, 
various other prognostic factors have also been described for 
EC, including histological type, grade, tumor size, myometrial 
invasion (MI) and lymph node metastasis (LNM) [7]. These 
prognostic factors can only be determined after extensive 
surgery [8], and so preoperative prognostic factors that are 
particulary important for patients who have comorbidities 
or for young patients who wish to preserve their fertility are 
sought. Also, some patients may survive even when faced 
with the same risk factors as those who do not survive, and 
additive prognostic factors are sought. F-18 fluorodeoxyglu-
cose (FDG) positron emission tomography (PET)/computed 
tomography (CT) is a widely used imaging method in patients 
diagnosed with malignancy. PET parameters have been sug-
gested to have a prognostic value in various cancer types such 
as lung cancer [9], esophageal cancer [10] and lymphoma 
[11–13]. There are, however, only a limited number of studies 
assessing the value of PET in determining the prognosis of EC. 
The present study investigates the relationship between 
the metabolic parameters of the primary tumor on preop-
erative PET/CT in patients with EC and overall survival (OS) 
and progression-free survival (PFS). The study also investi-
gates the prognostic value of certain clinicopathological 
factors in our patient population.
MATERIAL AND METHODS
Patients and follow-up
This retrospective study included 120 patients with 
a confirmed histopathological diagnosis of EC between April 
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2010 and May 2014 who underwent preoperative F-18 FDG 
PET/CT in our department. None of the patients underwent 
therapy prior to PET/CT, and after PET/CT they underwent 
a total hysterectomy, bilateral salpingo-oophorectomy and 
pelvic (± paraaortic) lymphadenectomy. Patients received ad-
juvant therapy involving chemotherapy and/or radiotherapy 
according to the histological subtype, grade and stages noted 
by the International Federation of Gynecology and Obstet-
rics (FIGO) 2009. Progression-free patients were followed up 
every 3 months for the first two years, every 6 months for 
2–5 years and once a year thereafter. As a matter of routine 
during the follow-up visits, medical histories were obtained, 
gynecological examinations were made, ultrasonographic 
data was recorded and serum cancer antigen 125 (CA125) 
levels were tested. Patients with suspected findings for recur-
rence underwent a pap smear, CT, MRI and/or PET/CT.
F-18 FDG PET/CT 
Images were taken from the base of the skull to the 
upper thigh by a PHILIPS GEMINI TF 16 Slice PET/CT device. 
After at least 6 hours of fasting, 0.15 mCi/kg F-18 FDG was 
injected into patients with a blood glucose level of less 
than 200 mg/dl. The patients were allowed to rest in a quiet 
room for one hour after the injection, after which the im-
ages were acquired. PET images were acquired in 9–10 bed 
positions, for 1.8 min per bed position. The CT images were 
used for attenuation correction.
The 3D region of interest (ROI) was drawn for the primary 
tumor, and the maximum standardized uptake value (SUV-
max) pertaining to the primary tumor in the region of interest 
was measured. SUVmean and metabolic tumor volume (MTV) 
were calculated, considering the recommended [14] 41% 
SUVmax as the threshold. The total lesion glycolysis (TLG) was 
calculated by multiplying the MTV by the SUVmean. 
Survival data and statistical analysis
OS was defined as the time from the date of diagnosis 
to the date of death from EC, or the time of last observation. 
PFS was defined as the time from the date of diagnosis to the 
date of progression or death. Survival curves were created 
for the patients using the Kaplan-Meier method. SUVmax, 
SUVmean, MTV, TLG values and patient age were considered 
as a continuous variable. The relationship between patient 
age, PET parameters related to the primary tumor (SUVmax, 
SUVmean, MTV, TLG) and OS and PFS was evaluated using 
the Cox proportional hazard model. The difference in OS 
and PFS between the groups classified according to the 
FIGO stage, the histological subtype, grade, size, MI, cervi-
cal invasion (CI), lymphovascular invasion (LVI) and distant 
metastasis was evaluated using the log-rank test. A value 
of p < 0.05 was considered statistically significant in the 
analyses. 
RESULTS
Patient characteristics
The study included 120 patients with a mean age of 
62.3 ± 0.02 years (range 42–85 years) who had been diagnosed 
histopathologically with EC. According to the FIGO classifica-
tion, 61 patients had stage 1, 26 had stage 2, five patients had 
stage 3 and 28 patients had stage 4 disease. Furthermore, 
67 patients had an endometrioid histology and the remaining 
53 patients had a non-endometrioid histology (mixed = 27, 
undifferentiated = 9, serous = 7, mucinous = 5, squamous = 4, 
clear cell = 1). Non-endometrioid subtypes were accepted 
as high-grade carcinoma. Eighteen of the patients with en-
dometrioid carcinoma were grade 1, 35 were grade 2, and 
14 were grade 3. The tumor size was ≥ 4 cm in 78 patients, MI 
was ≥ 50% in 69 patients, CI was positive in 29 patients, LVI was 
positive in 80 patients, pelvic or paraaortic LNM was positive 
in 13 patients and DM was positive in 17 patients. 
Survival
Of the total sample, 32 died around the time of the 
analysis and 38 patients showed disease progression. The OS 
and PFS were 32.7 ± 1.6 months and 30.5 ± 2.8 months, re-
spectively. When all patients are evaluated together in terms 
of the PET parameters of the primary tumor, the mean SU-
Vmax was 17.3 ± 0.07, the mean SUVmean was 8.6 ± 0.2, 
the mean MTV was 30.8 ± 0.01 mL and the mean TLG was 
295.2 ± 0.002 g. No significant relationship was identified 
between SUVmax, SUVmean, MTV, TLG values, patient age 
and OS and PFS (p > 0.05) (Tab. 1). Figures 1 and 2 present the 
PET parameters and survival data of the sample cases. There 
were no significant differences in terms of OS and PFS be-
tween the patients grouped according to tumor size (< 4 cm 
vs ≥ 4 cm), histology (endometrioid vs non-endometrioid), 
grade (grade1-2 vs grade 3) and MI degree (< 50% vs ≥ 50%) 
(p > 0.05). OS and PFS were lower in patients with advanced 
stage than in patients with early stage, in LVİ (+) patients 
than in LVI (-) patients, in CI (+) patients than in CI (-) patients, 
in LNM (+) patients than in LNM (-) patients, and in DM (+) 
patients than in DM (-) patients (Tab. 2). 
Table 1. Survival analysis results of PET parameters and age
Overall survival Progression free survival
p HR p HR
SUVmax 0.800 1.018 0.544 1.045
SUVmean 0.916 0.978 0.667 0.914
MTV 0.865 0.997 0.098 1.016
TLG 0.615 1.001 0.644 0.999
Age 0.820 1.007 0.414 1.022
SUVmax — maximum standardized uptake value;  MTV — metabolic tumor 
volume; TLG — total lesion glycolysis
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Figure 1. The MIP (A) and selected axial PET/CT (B, C) images of a 56-year-old patient with stage 4B undifferentiated endometrial cancer and 
a capsular implant in the liver are presented. Among the PET parameters of the primary tumor of the patient (A,B; arrows), SUVmax, SUVmean, MTV 
and TLG were found to be 3.8, 3, 1.2 mL and 3.6 g, respectively. The progression-free survival and overall survival of this patient were 6 months and 
17 months, respectively
Figure 2. The MIP (A) and fusion (B, C) images of a 61-year-old patient with stage 4B mix endometrial cancer and a capsular implant in the liver are 
presented. The PET parameters of the primary tumor of the patient (A, B; arrows) were calculated as follows: SUVmax: 24.4, SUVmean: 8.5, MTV: 17.8 
mL, and TLG: 151.3 g. The progression-free survival and overall survival of this patient were 8 months and 16 months, respectively
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DISCUSSION
Most patients with EC are diagnosed in the early stage 
(FIGO 1–2) [6]. Five-year survival rates are 74–91% in early 
stage disease, 57–66% in stage 3 and 20–26% in stage 4 [6]. 
Aside from the disease stage, tumor histology, grade, depth 
of MI, LVI, presence of LNM and the patient’s age can be count-
ed among the clinicopathological prognostic factors [15]. 
Tumor size and various molecular factors have also been 
suggested to be of prognostic value in studies, although this 
is still under research [15]. However, survival may be differ-
ent even in patients with the same risk factors. Furthermore, 
a large proportion of the known risk factors rely on staging 
during extensive surgery, which may be unnecessary in 
some patients with early-stage disease, and this is the sub-
ject of ongoing researches aimed at identifying preoperative 
noninvasive prognostic factors. FDG PET/CT is an effective 
imaging method that is used for initial diagnosis, staging, 
re-staging and evaluating response to therapy in a wide 
variety of cancers [16]. In the initial staging of endometrial 
cancer, PET/CT is recommended to detect extrauterine dis-
ease [17]. In addition, PET/CT has been shown to be useful 
in identifying candidates for surgical staging [18] and in 
determining post-operative recurrence [19]. But, only a lim-
ited number of studies evaluated the prognostic value of 
PET/CT in EC, and the results to date have been conflicting. 
In a study of 100 patients with stage 1–4 EC, Walentowicz-Sa-
dlecka et al. [8] identified significantly shorter OS in patients 
with a preoperative SUVmax ≥ 17.7 than in patients with 
a preoperative SUVmax of < 17.7. Another study involving 
42 patients with EC (stage 3C–4) found significantly longer 
OS in patients with a low SUVmax of the primary tumor 
(< 9.5) or lymph node (< 7.3) than in patients with a higher 
SUVmax [5]. In a study of 84 patients with stage 1–4 EC by 
Shim et al. [7], preoperative MTV and TLG were identified 
as independent prognostic factors for PFS in EC, although 
no significant relationship was identified between PFS and 
SUVmax and SUVmean, or between OS and MTV and TLG 
values. In a study by Liu et al. [20] involving 15 patients with 
stage 4B EC, whole body MTV and whole body TLG were 
found to be significant prognostic factors for survival. The 
present study found no significant relationship between 
the SUVmax, SUVmean, MTV and TLG values of the primary 
tumor and OS and PFS. The heterogeneity of the study popu-
lation in terms of such clinicopathological factors as stage, 
histology and grade is believed to be the cause of variety in 
the results. Furthermore, whole body measurements were 
carried out in the study by Liu et al., whereas the present 
study evaluated the PET parameters of the primary tumor. 
Such methodological differences may have also caused the 
differences in the results.
The present study identified FIGO stage, CI, LVI, and 
the presence of LNM and DM as prognostic factors for OS 
Table 2. Comparison of overall survival and progression free survival between the groups
n OS(mean ± SE, months) p
PFS
(mean ± SE, months) p
Stage 1–2 87 43.7 ± 1.3
< 0.001*
42.7 ± 1.5
< 0.001*
Stage 3–4 33 21.9 ± 4.5 13.9 ± 4.1
Tumor size < 4 cm 42 38.3 ± 3.0
0.881
36.6 ± 3.8
0.733
Tumor size ≥ 4cm 78 38.8 ± 2.2 36.0 ± 2.5
LVI (–) 40 44.3 ± 2.0
0.027*
44.3 ± 2.0
0.007*
LVI (+) 80 36.0 ± 2.6 31.9 ± 3.0
Endometroid 67 42.1 ± 2.1
0.156
41.1 ± 2.3
0.083
Nonendometroid 53 36.3 ± 2.9 32.1 ± 3.4
Grade1–2 53 42.8 ± 2.1
0.190
41.6 ± 2.3
0.142
Grade 3 67 36.7 ± 2.7 33.0 ± 3.1
MI < 50% 51 42.4 ± 1.9
0.163
41.0 ± 2.3
0.106
MI ≥ 50% 69 36.2 ± 3.0 32.7 ± 3.3
CI (–) 91 42.6 ± 1.5
< 0.001*
41.6 ± 1.8
< 0.001*
CI (+) 29 25.8 ± 4.8 17.8 ± 4.6
LNM (–) 107 41.0 ± 1.7
0.001*
39.3 ± 1.9
< 0.001*
LNM (+) 13 17.8 ± 4.8 9.1 ± 3.7
DM (–) 103 40.9 ± 1.7
< 0.001*
39.2 ± 2.0
< 0.001*
DM (+) 17 17.4 ± 3.7 8.0 ± 2.2
OS — overall survival; PFS — progression free survival; LVI — lymphovascular invasion; MI — myometrial invasion; CI — cervical invasion; LNM — lymph node 
metastasis; DM — distant metastasis; significant values (P < 0.05) are indicated with *
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and PFS, while age, tumor diameter, histology, grade, and 
MI were not found to be related to OS and PFS. Various 
risk classification systems have been developed to predict 
prognosis and to guide treatment of endometrial cancer. 
Risk factors such as FIGO stage, tumor histology, grade, 
MI and LVI are evaluated together in these classification 
systems [15]. However, in our study, we discussed the risk 
factors one by one. And so, the non-homogeneous distri-
bution of other prognostic factors across the age groups 
and patients classified in terms of tumor histology, grade, 
diameter and MI degree, may have also resulted in the differ-
ence in the current findings. For example, LNM was mostly 
present in patients aged < 62 years. In a meta-analysis in-
cluding 14 studies (672 patients), complete cytoreduction 
to no gross residual disease for patients with advanced or 
recurrent endometrial cancer was found to be associated 
with superior overall survival outcome [21]. However, we 
did not evaluate the presence of post-treatment residual 
tumor. Furthermore, although all patients in the present 
study underwent surgery, post-operative treatments were 
not standard. Differences in the treatment management 
may have contributed to current results. In addition, some 
micrometastases may not be detected during surgery or 
by PET/CT. The presence of undetectable micrometastasis 
may also have affected prognosis. AlHilli et al. [22] declared 
a relationship between tumor diameter and survival. In that 
study, 2 cm was utilized for the cut-off value of the tumor 
size [22]. But we used a threshold of 4 cm that may have 
caused us to find a different result.
In the present study, 5-year survival rates were not evalu-
ated and there were limitations such as relatively short 
follow-up period and retrospective design.
CONCLUCIONS
No significant relationship was found between PET pa-
rameters and OS and PFS, and so prospective studies involv-
ing a larger number of patients with more homogeneous 
groups are needed. 
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